Secukinumab Reduces Endothelial Dysfunction in Subjects with Moderate-to-Severe Plaque Psoriasis Over 52 Weeks: Results of the Exploratory CARIMA Study. J of Skin. 2018;2(S1):S20. doi:10.25251/skin.2.supp.20